Novartis is a Swiss multinational pharmaceutical corporation headquartered in Basel. The company was formed in 1996 through the merger of Ciba-Geigy and Sandoz and is one of the world’s largest pharmaceutical companies.
Health care stocks rallied late in the week as Moderna beat Q4 expectations and reiterated its revenue outlook, lifting the sector. Novartis and AstraZeneca posted encouraging Phase 3 results, while Opus Genetics announced a $25 million private placement.
Novartis AG will transfer its 70.68% stake in NIL to ChrysCapital, with closing expected in Q3 2026. NIL plans therapy-aligned acquisitions and deeper Tier 2-3 reach across five anchor therapy areas.
Positive Phase III results for remibrutinib in relapsing MS: primary endpoints met, relapse rate reduced vs teriflunomide, no liver safety signal. A chronic inducible urticaria trial also met endpoints.
Biocryst will present Orladeyo and navenibart data at AAAAI; BioAge is advancing BGE-102 into a Phase 2 cardiovascular trial; Alebund reported interim results including NMPA acceptance of AP301.
Novartis has posted job openings for an Associate Expert Drug Supply in Slovenia (€20,300–€37,700), an Associate Director, Solutions Delivery Clinical Analytics in New Jersey ($180,090–$185,000), and an Associate Director, Program Launch and Change Excellence ($145,600–$270,400).
The WHO approved the first malaria drug for infants weighing under 5kg, and researchers unveiled a single-dose compound, cabamiquine, showing promise in early trials. Investment in the Medicines for Malaria Venture yielded $13 in health benefits per $1 invested, averting 1.6 million deaths.
Alnylam reported Q4 2025 adjusted EPS of $1.25, beating estimates, while revenue of $1.10 billion missed consensus despite 85% growth. Amvuttra sales surged 189% to $826.6 million. The stock fell 4.1% after the mixed results.
Novartis marks 30 years since its 1996 merger, citing advances in targeted therapy, cell therapy, gene therapy, and malaria. It also named a Levant Country President and won two clinical research awards in Saudi Arabia.
AI is transforming drug discovery across target ID, molecule design and trial optimization. Milestones include regulatory qualification of digital-twin controls and positive Phase 2a data, though 90-95% of candidates still fail.
AI drug discovery is moving from hype to proof in 2026, with multi-billion-dollar partnerships, new joint initiatives, and major investments accelerating AI-native biotech pipelines and data-driven deals.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07758270 |
Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis. |
RECRUITING | |
| NCT07676877 |
Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma |
NOT_YET_RECRUITING | PHASE1 |
| NCT07618390 |
A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer. |
NOT_YET_RECRUITING | PHASE2 |
| NCT07549646 |
24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07549139 |
Overcoming Racial Disparities in Screening Mammography |
NOT_YET_RECRUITING | NA |
| NCT07543822 |
24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07538401 |
ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07493408 |
Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML |
NOT_YET_RECRUITING | PHASE2 |
| NCT07443137 |
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07434180 |
Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary |
NOT_YET_RECRUITING | PHASE2 |
